Original
Análisis de minimización de costes entre fingolimod y natalizumab en segunda línea de tratamiento de esclerosis múltiple remitente-recurrente
Cost minimisation analysis of fingolimod vs natalizumab as a second line of treatment for relapsing-remitting multiple sclerosis
a Departamento de Estadística, Universidad de Barcelona, Barcelona, España
b Oblikue Consulting, Barcelona, España
c Unidad de Esclerosis Múltiple, Hospital Universitario Virgen de la Macarena, Sevilla, España
d Departamento de Farmacología y Terapéutica Clínica, Facultad de Medicina, Universidad de Málaga, Málaga, España
e Novartis Farmacéutica, Barcelona, España
Leído
7038
Vecesse ha leído el artículo
1590
Total PDF
5448
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 12 | 24 | 5 | 29 |
| 2025 11 | 46 | 25 | 71 |
| 2025 10 | 41 | 17 | 58 |
| 2025 9 | 30 | 17 | 47 |
| 2025 8 | 61 | 16 | 77 |
| 2025 7 | 49 | 12 | 61 |
| 2025 6 | 42 | 4 | 46 |
| 2025 5 | 88 | 7 | 95 |
| 2025 4 | 64 | 5 | 69 |
| 2025 3 | 54 | 6 | 60 |
| 2025 2 | 56 | 7 | 63 |
| 2025 1 | 65 | 2 | 67 |
| 2024 12 | 39 | 3 | 42 |
| 2024 11 | 37 | 7 | 44 |
| 2024 10 | 34 | 10 | 44 |
| 2024 9 | 49 | 20 | 69 |
| 2024 8 | 47 | 11 | 58 |
| 2024 7 | 35 | 6 | 41 |
| 2024 6 | 66 | 1 | 67 |
| 2024 5 | 77 | 5 | 82 |
| 2024 4 | 54 | 8 | 62 |
| 2024 3 | 47 | 10 | 57 |
| 2024 2 | 69 | 10 | 79 |
| 2024 1 | 50 | 3 | 53 |
| 2023 12 | 46 | 9 | 55 |
| 2023 11 | 46 | 9 | 55 |
| 2023 10 | 66 | 9 | 75 |
| 2023 9 | 36 | 11 | 47 |
| 2023 8 | 28 | 8 | 36 |
| 2023 7 | 19 | 8 | 27 |
| 2023 6 | 24 | 5 | 29 |
| 2023 5 | 16 | 5 | 21 |
| 2023 4 | 21 | 6 | 27 |
| 2023 3 | 10 | 3 | 13 |
| 2023 2 | 23 | 2 | 25 |
| 2022 1 | 32 | 8 | 40 |
| 2022 12 | 33 | 10 | 43 |
| 2022 11 | 56 | 7 | 63 |
| 2022 10 | 18 | 8 | 26 |
| 2022 9 | 25 | 26 | 51 |
| 2022 8 | 36 | 9 | 45 |
| 2022 7 | 34 | 10 | 44 |
| 2022 6 | 29 | 6 | 35 |
| 2022 5 | 42 | 14 | 56 |
| 2022 4 | 86 | 11 | 97 |
| 2022 3 | 121 | 15 | 136 |
| 2022 2 | 132 | 16 | 148 |
| 2021 1 | 79 | 11 | 90 |
| 2021 12 | 56 | 24 | 80 |
| 2021 11 | 62 | 16 | 78 |
| 2021 10 | 22 | 15 | 37 |
| 2021 9 | 16 | 13 | 29 |
| 2021 8 | 11 | 7 | 18 |
| 2021 7 | 44 | 15 | 59 |
| 2021 6 | 21 | 15 | 36 |
| 2021 5 | 31 | 9 | 40 |
| 2021 4 | 41 | 38 | 79 |
| 2021 3 | 35 | 16 | 51 |
| 2021 2 | 18 | 10 | 28 |
| 2020 1 | 31 | 10 | 41 |
| 2020 12 | 19 | 10 | 29 |
| 2020 11 | 26 | 11 | 37 |
| 2020 10 | 15 | 12 | 27 |
| 2020 9 | 17 | 6 | 23 |
| 2020 8 | 24 | 3 | 27 |
| 2020 7 | 18 | 8 | 26 |
| 2020 6 | 15 | 8 | 23 |
| 2020 5 | 29 | 14 | 43 |
| 2020 4 | 16 | 5 | 21 |
| 2020 3 | 29 | 12 | 41 |
| 2020 2 | 21 | 16 | 37 |
| 2020 1 | 22 | 4 | 26 |
| 2019 12 | 47 | 12 | 59 |
| 2019 11 | 23 | 20 | 43 |
| 2019 10 | 20 | 4 | 24 |
| 2019 9 | 25 | 8 | 33 |
| 2019 8 | 12 | 4 | 16 |
| 2019 7 | 27 | 16 | 43 |
| 2019 6 | 58 | 25 | 83 |
| 2019 5 | 168 | 38 | 206 |
| 2019 4 | 96 | 28 | 124 |
| 2019 3 | 20 | 6 | 26 |
| 2019 2 | 63 | 29 | 92 |
| 2019 1 | 29 | 11 | 40 |
| 2018 12 | 37 | 4 | 41 |
| 2018 11 | 52 | 12 | 64 |
| 2018 10 | 43 | 16 | 59 |
| 2018 9 | 59 | 11 | 70 |
| 2018 8 | 52 | 7 | 59 |
| 2018 7 | 9 | 8 | 17 |
| 2018 6 | 7 | 3 | 10 |
| 2018 5 | 5 | 4 | 9 |
| 2018 4 | 5 | 2 | 7 |
| 2018 3 | 10 | 3 | 13 |
| 2018 2 | 4 | 2 | 6 |
| 2018 1 | 13 | 13 | 26 |
| 2017 12 | 13 | 1 | 14 |
| 2017 11 | 21 | 6 | 27 |
| 2017 10 | 21 | 4 | 25 |
| 2017 9 | 9 | 4 | 13 |
| 2017 8 | 34 | 2 | 36 |
| 2017 7 | 17 | 2 | 19 |
| 2017 6 | 23 | 19 | 42 |
| 2017 5 | 23 | 12 | 35 |
| 2017 4 | 11 | 12 | 23 |
| 2017 3 | 26 | 24 | 50 |
| 2017 2 | 26 | 8 | 34 |
| 2016 1 | 36 | 5 | 41 |
| 2016 12 | 38 | 9 | 47 |
| 2016 11 | 49 | 9 | 58 |
| 2016 10 | 51 | 13 | 64 |
| 2016 9 | 42 | 25 | 67 |
| 2016 8 | 27 | 13 | 40 |
| 2016 7 | 19 | 10 | 29 |
| 2016 6 | 31 | 12 | 43 |
| 2016 5 | 33 | 24 | 57 |
| 2016 4 | 29 | 17 | 46 |
| 2016 3 | 35 | 29 | 64 |
| 2016 2 | 28 | 13 | 41 |
| 2015 1 | 29 | 10 | 39 |
| 2015 12 | 47 | 13 | 60 |
| 2015 11 | 49 | 16 | 65 |
| 2015 10 | 58 | 14 | 72 |
| 2015 9 | 61 | 12 | 73 |
| 2015 8 | 73 | 11 | 84 |
| 2015 7 | 60 | 20 | 80 |
| 2015 6 | 16 | 8 | 24 |
| 2015 5 | 29 | 11 | 40 |
| 2015 4 | 27 | 17 | 44 |
| 2015 3 | 32 | 10 | 42 |
| 2015 2 | 46 | 8 | 54 |
| 2015 1 | 39 | 12 | 51 |
| 2014 12 | 31 | 9 | 40 |
| 2014 11 | 26 | 11 | 37 |
| 2014 10 | 32 | 10 | 42 |
| 2014 9 | 35 | 14 | 49 |
| 2014 8 | 28 | 13 | 41 |
| 2014 7 | 33 | 17 | 50 |
| 2014 6 | 34 | 20 | 54 |
| 2014 5 | 216 | 35 | 251 |
Mostrar todo
